Chemobrain in rats: Behavioral, morphological, oxidative and inflammatory effects of doxorubicin administration

Behav Brain Res. 2020 Jan 27:378:112233. doi: 10.1016/j.bbr.2019.112233. Epub 2019 Sep 12.

Abstract

Doxorubicin (DOX) is known to cause cognitive impairments in patients submitted to long-term chemotherapy (deficits also known as chemobrain). The present study investigated whether DOX administration could affect behavior and brain morphology, as well as oxidative and inflammatory status in rats. Male Wistar rats were injected with DOX (2.5 mg/kg/week, 4 weeks, i.p.) or saline. Behavioral analyses were performed. Brains were collected and analyzed by hematoxylin-eosin and luxol fast blue staining techniques and by immunohistochemistry (for glial fibrillary acidic protein expression in astrocytes; GFAP). Serum and brain levels of TNF-α, IL-1β, IL-6, IL-8, IL-10 and CXCL-1 were determined. Oxidative parameters, such as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GR), nitric oxide (NO•), brain iron and ferritin levels, as well as reduced and oxidized glutathione (GSH and GSSG, respectively) and thiobarbituric acid reactive substances (TBARS) were also assessed in brain. DOX-injected rats presented cognitive/memory impairments, increased GFAP expression, increased levels of TBARS, NO and GR, but decreased GSSG and ferritin levels in brain homogenate. In addition, increased serum and brain levels of IL-6, IL-8 and CXCL1 were noted in the DOX group, although IL-10 decreased. As DOX has a poor penetration across the blood-brain barrier (BBB), it is proposed that this drug elicits a systemic proinflammatory response with increase of proinflammatory cytokines which cross the BBB and can be involved in the induction of oxidative molecules and proinflammatory cytokines that altogether induce astrogliosis all over the brain. These events may be responsable for chemotherapy-induced cognitive/memory deficits.

Keywords: Astrocytes; Chemotherapy; Cytokines; Glial fibrillary acidic protein; Memory impairment; Oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / adverse effects*
  • Behavior, Animal / drug effects*
  • Brain / drug effects*
  • Brain / immunology
  • Brain / metabolism
  • Brain / pathology
  • Cognitive Dysfunction / chemically induced*
  • Cognitive Dysfunction / metabolism
  • Cognitive Dysfunction / pathology
  • Cognitive Dysfunction / physiopathology
  • Cytokines / blood
  • Cytokines / metabolism*
  • Doxorubicin / adverse effects*
  • Gliosis / chemically induced*
  • Inflammation / chemically induced*
  • Inflammation / immunology
  • Inflammation / metabolism
  • Male
  • Memory Disorders / chemically induced*
  • Memory Disorders / metabolism
  • Memory Disorders / pathology
  • Memory Disorders / physiopathology
  • Oxidative Stress / drug effects*
  • Rats
  • Rats, Wistar

Substances

  • Antibiotics, Antineoplastic
  • Cytokines
  • Doxorubicin